Quintrigen Overview
- Year Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
Joint Venture
- Financing Rounds
-
1
Quintrigen General Information
Description
Developer of P53 anticancer drugs based in Tel Aviv-Yafo, Israel. The company develops and promotes the commercialization of a technology that inhibits or kills cancer cells by reactivating damaged p53 by binding a specific peptide.
Contact Information
Corporate Office
- Tel Aviv
- Israel
Corporate Office
- Tel Aviv
- Israel
Quintrigen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Quintrigen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Quintrigen FAQs
-
When was Quintrigen founded?
Quintrigen was founded in 2019.
-
Where is Quintrigen headquartered?
Quintrigen is headquartered in Tel Aviv, Israel.
-
What industry is Quintrigen in?
Quintrigen’s primary industry is Drug Discovery.
-
Is Quintrigen a private or public company?
Quintrigen is a Private company.
-
What is Quintrigen’s current revenue?
The current revenue for Quintrigen is .
-
Who are Quintrigen’s investors?
Moa Life Plus and YEDA Technology Transfer have invested in Quintrigen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
